ASTRO 2023: Exploring the Potential for SBRT in Prostate and Kidney Cancer

Martin T. King, MD, PhD

October 09, 2023

Martin T. King, MD, PhD, explores two studies presented at the ASTRO 2023 annual meeting concerning the therapeutic potential of stereotactic body radiotherapy (SBRT). The first, the PACE-B trial, addresses patients with favorable-risk prostate cancer; the second, FASTRACK II, focuses on inoperable kidney cancer.

The common denominator for both studies is the potential for SBRT. In prostate cancer, King emphasizes how these results could justify SBRT becoming a standard-of-care option for low- or predominately favorable intermediate-risk disease. In kidney cancer, SBRT could be a suitable therapy for both small and large medically inoperable tumors; continued research into its utilization is warranted.

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: ASTRO 2023: Exploring the Potential for SBRT in Prostate and Kidney Cancer - Medscape - Oct 09, 2023.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.